Tag
A 10-year follow-up of early rheumatoid arthritis patients treated with a treat-to-target strategy shows sustained remission leads to lasting clinical, structural, and functional benefits, supporting current treatment guidelines.
A newly developed weighted flare scoring system in SLE accurately predicts organ damage accumulation, outperforming traditional flare classifications and informing treat-to-target strategies.
Achieving serum urate targets <6 mg/dL (or <5 mg/dL) through Treat-to-Target (T2T) protocols significantly reduces major adverse cardiovascular events in gout patients, particularly those at high baseline risk.
The STAMP randomized trial found that a treat‑to‑target strategy starting with secukinumab plus methotrexate did not achieve superior 6‑month ACR50 rates versus a conventional methotrexate‑first step‑up approach; 12‑month outcomes were simi
Early secukinumab use in newly diagnosed psoriatic arthritis delivers faster clinical improvement at 3 months compared to standard care, but this advantage diminishes by 6 months and beyond.
